GA
PBLS

General Atlantic’s Parabilis Medicines Inc PBLS Stock Holding History

General Atlantic’s Portfolio PBLS Stock Details PBLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.1M Buy
+1,538,461
New +$42.5M 1.45% 10

Other funds holding PBLS

VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

General Atlantic's PBLS Position: Q2 2026 in Review

General Atlantic opened a new position in Parabilis Medicines Inc (PBLS) in Q2 2026: 1,538,461 shares worth $42.1M. The stake represents 1.45% of the portfolio and ranks #10 among its holdings.

63 funds tracked by Wall St. Rank hold PBLS as of Q2 2026.

  • General Atlantic held 1,538,461 shares of Parabilis Medicines Inc worth $42.1M as of Q2 2026.
  • Parabilis Medicines Inc was a new General Atlantic position in Q2 2026.
  • Parabilis Medicines Inc made up 1.45% of General Atlantic's portfolio in Q2 2026, its #10 holding.
  • 63 funds tracked by Wall St. Rank held Parabilis Medicines Inc as of Q2 2026.

Based on General Atlantic's 13F filing for Q2 2026, filed 14 Aug 2026.